- The 26S proteasome is a large ATP‑dependent protease complex responsible for degrading ubiquitinated proteins in eukaryotic cells. It forms the central machinery of the ubiquitin–proteasome system, ensuring selective removal of damaged, misfolded, or short‑lived regulatory proteins. By controlling protein turnover, the 26S proteasome maintains cellular homeostasis, regulates signalling pathways, and supports essential processes such as cell‑cycle progression, immune responses, and stress adaptation. Its precision and efficiency make it one of the most important molecular machines in modern cell biology.
- The 26S proteasome consists of two major components: the 20S core particle (CP) and one or two 19S regulatory particles (RP). The 20S core is a cylindrical structure composed of four stacked rings: two outer α‑rings and two inner β‑rings. The β‑subunits contain the proteolytic active sites responsible for peptide bond cleavage. The 19S regulatory particle caps the core and performs several essential functions, including recognising ubiquitinated substrates, removing ubiquitin chains, unfolding proteins, and translocating them into the 20S core for degradation. Together, these components form a highly coordinated system that ensures selective and efficient proteolysis.
- The degradation process begins when the 19S regulatory particle recognises proteins tagged with polyubiquitin chains, typically linked through lysine‑48. Substrate recognition is followed by deubiquitylation, mediated by deubiquitinating enzymes associated with the proteasome. Once ubiquitin is removed and recycled, the regulatory particle uses ATP‑dependent unfolding mechanisms to prepare the substrate for entry into the narrow catalytic chamber of the 20S core. Inside the core, proteolytic sites cleave the protein into short peptides, which are subsequently released into the cytosol for further processing or recycling.
- The 26S proteasome plays a central role in cell‑cycle regulation by degrading cyclins and other regulatory proteins at specific checkpoints. This ensures orderly progression through G1, S, G2, and M phases. In signal transduction, the proteasome terminates signalling events by removing activated receptors, transcription factors, and kinases. For example, degradation of IκB allows NF‑κB activation, while subsequent proteasomal turnover of signalling intermediates ensures timely resolution of inflammatory responses.
- In immune cells, the proteasome generates antigenic peptides for presentation on MHC class I molecules. Specialised forms known as immunoproteasomes enhance the production of peptides with optimal binding properties, improving immune recognition of infected or abnormal cells. The proteasome also regulates cytokine production, T‑cell activation, and innate immune signalling, making it indispensable for host defence.
- Proteasome dysfunction has severe consequences. Impaired proteasome activity leads to accumulation of misfolded or toxic proteins, contributing to neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and Huntington’s disease. In cancer, altered proteasome function stabilises oncogenic proteins and supports uncontrolled proliferation. As a result, proteasome inhibitors such as bortezomib and carfilzomib are used clinically to treat multiple myeloma and other malignancies. Emerging technologies like PROTACs exploit the proteasome to selectively degrade disease‑associated proteins, offering new therapeutic possibilities.
- Overall, the 26S proteasome is a highly sophisticated molecular machine essential for maintaining protein quality and regulating cellular behaviour. Its ability to selectively degrade ubiquitinated proteins ensures precise control over countless biological processes. Understanding proteasome structure and function provides valuable insight into disease mechanisms and supports the development of targeted therapies.
